Directory · GB
Biotechnology Research in United Kingdom
A register of firms and the professionals working at them in the Biotechnology Research sector based in United Kingdom. Browse the public index, then filter or export on Kipplo.
Companies
2.1K on file
Fisher Scientific
As the premier scientific marketplace, we have defined unparalleled choice and convenience for over a century. Focused first and foremost on delivering innovative yet eminently practical solutions, we have developed a comprehensive portfolio of lab and production essentials—everything from chemicals, diagnostics, and laboratory, safety, and teaching supplies to support services, manufacturing materials, and more—to help our customers increase productivity and drive innovation in research, healthcare, education, and industry, all with greater ease and efficiency than ever before. Connect with the Fisher Scientific team, a part of Thermo Fisher Scientific, and learn about the latest ways we’re empowering teams like yours to achieve even more. Our Mission at Thermo Fisher Scientific is to enable our customers to make the world healthier, cleaner and safer.
10001+ staff
Icon Plc
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
10001+ staff
Ab Vista
AB Vista is an animal nutrition technology company offering pioneering products and technical services to the global animal feed industry. Since its establishment in 2004, AB Vista has grown to be a top-three player in feed enzymes and is also one of the largest suppliers of natural betaine to the global animal nutrition industry. The company invests heavily in research and development and has a growing portfolio of products and services spanning the poultry, swine, ruminant and aquaculture sectors. AB Vista aims to bring a broader knowledge base to the global feed industry through close collaboration with customers and academics, identifying new and exciting opportunities for improved feed and animal performance. AB Vista is headquartered in the UK, with regional offices located in the USA, Brazil, Singapore, Spain, India, China, Germany and Finland. AB Vista is part of AB Agri, the agricultural division of Associated British Foods (ABF plc), one of Europe’s largest food & retail companies with a market capitalisation of £25 billion.
51 to 200 staff
Advanced Instruments, Llc
Advanced Instruments has merged with Nova Biomedical, uniting two innovation-driven organizations to form a larger, global life science tools company operating under the Nova Biomedical name. This strategic combination broadens our expertise in bioprocessing and clinical diagnostics, strengthening our capacity to serve customers and create lasting impact across the life sciences and healthcare industries. You will see branding changes with our official name change transition happening in the fall. Our focus on service, quality, and reliability has made Advanced Instruments a leading developer and manufacturer of analytical instruments and services for the biopharmaceutical, clinical, and food & beverage industries for over 70 years. We provide innovative technologies aligned with the needs of the markets we serve, helping to improve efficiency, enhance productivity, and ensure best-in-class performance. Our Solentim portfolio of imaging and single-cell deposition technologies enables the clonal isolation, outgrowth, and characterization of high-value cells for monoclonal antibody development and cell and gene therapy. Our micro-osmometers are built for biotech and integrate into GMP and non-GMP workflows to ensure yield, quality, and purity. Clinical labs worldwide rely on our solutions for chemistry, microbiology, and hematology to deliver accurate, timely results and streamline workflows. Our Artel portfolio includes instruments, software, and services that validate, automate, and calibrate critical liquid handling processes. We are supported by a global network of direct sales and distributors, with 24/7 technical support. Interested in joining a dynamic team? Let’s connect. For more information, visit
201 to 500 staff
Alloy Therapeutics, Inc
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecule's potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloy's affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together.
51 to 200 staff
Molecular Devices
Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over peer-reviewed publications. Over of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif, with best-in-class teams around the globe. Over associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion. Molecular Devices is proud to be part of Danaher. Danaher’s science and technology leadership puts Molecular Devices’ solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. To learn more about how Molecular Devices helps fast-track scientific discovery, visit
1001 to 5000 staff
Promega Corporation
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints. We develop and evolve technologies and instrumentation in collaboration with scientists and researchers around the globe. From simple cloning vectors used to address fundamental questions in biology to bioluminescent assays that help us monitor food safety and water quality, we work side-by-side with our partners in academic, industrial and government institutions to bring the best minds to bear on the toughest questions. Since 1978, we have done this all with a steadfast commitment to sustainable business models that protect our environment, inspire and develop our employees as individuals, support the wellbeing and growth of our communities, and strengthen our relationships with our customers. With 16 branches around the world, Promega products are used by a global community of life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.
1001 to 5000 staff
R&d Systems
R&D Systems, by Bio-Techne, is a trusted partner to scientists around the world. For nearly 50 years, we've supported discovery to clinical research and application with high-performance and quality proteins, small molecules, antibodies, and immunoassays used in research areas including cancer, autoimmune disease, inflammation, and neurobiology. R&D Systems solutions work in concert with Tocris Bioscience small molecules, Novus Biologicals antibodies, and ProteinSimple automated protein analytical instruments to accelerate breakthroughs across research, diagnostics, and therapeutics. Learn more at
1001 to 5000 staff
Vernalis
We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation. Our established group of experienced scientists is based at our fully-equipped research laboratories on Granta Park, Cambridge UK. We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive medicinal chemistry expertise to enable drug discovery on both established and novel targets. We have the experience and capabilities for progressing projects from target identification through to clinical candidate. We have generated lead compounds on kinases, ATPases, protein-protein interactions and GPCRs, leading to clinical candidates for Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A. We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and we seek additional partnerships.
51 to 200 staff
Vertex Pharmaceuticals
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and has made significant advancements in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain — and continues to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Our global headquarters is in Boston, and we have research and development (R&D) sites and commercial offices worldwide. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards. Read our community guidelines:
5001 to 10000 staff
Bit.Bio
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit
51 to 200 staff
Genomics England
Genomics England works with the NHS to bring forward the use of genomic healthcare and research in Britain to help people live longer, healthier lives. Genomics is a ground-breaking area of medicine that uses our unique genetic code to help diagnose, treat and prevent illnesses. Thanks to advanced technology, scientists can now compare many people’s genetic code to make new discoveries that continually improve genomic healthcare. In 2013, Genomics England and the NHS launched the Genomes Project, demonstrating how genomics insights can help doctors across the NHS, and building a foundation for the future by assembling a unique dataset. Genomics England is now supporting the NHS to deliver genomic testing for patients as part of routine healthcare, and providing the health data and technology that researchers need to make new discoveries and create more effective, targeted medicines. We work with thousands of people – patients, doctors and scientists – to increase our collective knowledge and enable faster and deeper genomic research, to bring genomic healthcare to all who need it.
201 to 500 staff
Hvivo
hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
51 to 200 staff
Lab M Ltd
Lab M specialises in the development, manufacture and supply of microbiological culture media. Lab M is a Neogen company (NASDAQ: NEOG) and operates from headquarters in Heywood, Greater Manchester, UK, which house all R&D, technical support, manufacturing and commercial operations. A direct team in the UK and a network of trusted distribution partners service Europe, the Middle East and Africa with support from Neogen Corporation elsewhere around the world providing local sales and support. Established in 1971, Lab M has long enjoyed an international reputation for the high quality of its dehydrated culture media. Its R&D teams work in collaboration with key institutions and industry leaders to develop and trial new products that give faster results at lower cost. As well as a comprehensive offering of well-known microbiological media, there are a number of distinct and increasingly important brands within the Lab M portfolio: Harlequin™, a range of chromogenic media that now includes Salmonella, Listeria, Escherichia coli and Cronobacter sakazakii detection; Captivate™, the immunomagnetic separation system designed to speed up the culture and isolation of specific organisms, with a focus on STECs in foodstuffs; and µPREP™, a new line of bagged, sterile, ready-to-reconstitute media for high throughput applications. Lab M also supplies bulk peptones, extracts and other raw materials of plant and animal origin to pharmaceutical and large-scale fermentation industries, in compliance with current EDQM certification. Custom-designed and custom-blended products are also produced. Lab M is certified in accordance with ISO 9001:2008 and ISO 13485:2003 products designed for the clinical market are supplied in compliance with the European IVD directive and carry the CE mark. Lab M was acquired by Neogen in August 2015. Neogen is a global leader in the development and marketing of products dedicated to food and animal safety.
11 to 50 staff
Neogen Iemea
NEOGEN iEMEA is a subsidiary of Neogen Corporation. We are present through direct teams in UK, Ireland, France, Germany, the Netherlands and Italy, and through distributors across all of Europe, Middle East and Africa and India. NEOGEN provides the most comprehensive range of solutions for the food processing, animal protein and agriculture industries, not only protecting the world’s food supply, but also allowing our customers to produce more efficiently and effectively than they could before. Our Food Safety product range covers culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, hygiene indicators and much more. Through our Animal Safety range, we offer veterinary instruments and supplies, cleaners and disinfectants for farm and veterinary settings, insecticides and rodenticides to limit the spread of disease and more. And we offer Genomics solutions that allow animal protein producers to make educated breeding decisions that improve the efficiencies of their herds, breed associations to verify parentage, and for food safety professionals to identify bacterial strains associated with particular disease outbreaks. In addition, our forensic toxicology and life science kits are used by many leading organizations around the world.
201 to 500 staff
Oxitec
Oxitec is a team of passionate individuals from 15 countries improving lives and livelihoods by developing the world's first safe, self-limiting technology to control pests that transmit diseases, destroy crops and harm livestock. Our technology platform allows us to build safe, non-toxic, species-specific, and self-limiting control solutions to a range of damaging insects. We work in close partnerships with governments, foundations, companies and communities around the world and have demonstrated excellence in targeted insect suppression, biosafety, environmental sustainability, regulatory approvals, public acceptance, and scalability. We are growing, so people who share our desire to have impact globally are encouraged to get in touch.
51 to 200 staff
Quell Therapeutics
An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.
51 to 200 staff
Anitox
We partner with the world’s food producers to develop and deliver innovative programs to efficiently produce safer food. Security through Science™
51 to 200 staff
Astex Pharmaceuticals
Astex Pharmaceuticals is a world leader in innovative drug discovery. Our research teams utilize a cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS. The company has successfully applied its proprietary Fragment-Based Drug Discovery (FBDD) platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations with Pharma partners have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ from AstraZeneca). Astex continues to grow in Cambridge, UK and has opportunities for experienced and innovative scientists wishing to develop their careers in a thriving multidisciplinary, industrial environment. For more information about Astex or for job opportunities, please visit our website below.
51 to 200 staff
Bio Basic Inc
Bio Basic Inc. is a biotechnology company founded in Toronto, Canada. Since its inception, Bio Basic has developed rapidly by manufacturing various Life Science Products and has served as a one-stop-stop for researchers in the Life Sciences. Bio Basic strongly committed to innovation and excellence. It strives to do so by directing its efforts into R&D and improving the quality of its products. Bio Basic offers a wide variety of products and services, especially in the field of molecular biology. Several product lines from Bio Basic such as, Molecular Biology Kits, Biochemicals, Synthetic Genes, Peptides and Oligomers have already shown a dominant market presence and have been widely recognized by researchers worldwide. Bio Basic distinguishes itself from our other competitors by: 1. Being a direct manufacturer of its own product lines, thereby guaranteeing the most competitive prices on the market. Providing a wide range of products and services, to assist with many areas of Life Science Research. Strict quality control – Bio Basic ensures that the quality of its products and services meet the highest in global standards through continuous process improvement and vigorous R&D. Its mission to make high quality research products and services affordable to any lab. Bio Basic's Product Lines: Molecular Biology Kits Culture Media Biochemicals Electrophoresis Reagents (including DNA, RNA and Protein Markers) PCR Reagents Pre-made Recombinant Protein Labware Benchtop Equipment Bio Basic's Services: Gene Synthesis Oligo Synthesis Protein Production Peptide Synthesis Antibody Production DNA Sequencing Our Mission: “To provide the highest quality products and services at the most affordable rates in the industry”. Our Vision: “To make quality research affordable to any lab, anywhere, thereby allowing scientific breakthroughs to ourish”. Our Values: “To deliver an unparalleled quality of service as a team with great care, passion and integrity”.
51 to 200 staff
It's Fresh
We're a UK-based Agri-Food Tech company solving the fresh produce ethylene problem … in a much more sustainable way. Based in Staffordshire, we're commercializing innovative solutions for the post-harvest and retail sectors. Addressing the impacts of ethylene in a fundamentally new way, our products can extend all the way to consumers’ homes. While there are many factors affecting the quality and shelf-life of fresh produce—things like agronomy best practice, harvesting approaches and post-harvest conditions on temperature, humidity, microbial controls, and time in transit—the management of the plant hormone ethylene is perhaps the most crucial. Without ethylene management, the extensive efforts on those other factors is effectively wasted; with it, and the produce is protected, reducing its stress and extending its life. Unlike other solutions, the It’s Fresh technology does not interfere with the natural pathways, or cover the produce with coatings. Instead, it manages and adsorbs ethylene, allowing the produce to develop naturally, albeit at a slower rate. This means produce protected with It’s Fresh simply tastes and smells better. We have now launched our second-generation technology (Active) with up to 10x the efficacy of our first generation. With ethylene-control products that are both customisable and seamlessly integrable, we support better returns for growers and retailers, and ultimately better eating outcomes for consumers, reducing waste across the supply chain at the same time.
11 to 50 staff
Lgc
We are a global leader in life science tools, partnering with customers to find solutions that diagnose, treat, feed and protect our growing population. Working collaboratively with our partners in the scientific community, our products and services help to solve some of the most complex challenges facing society and the planet. Together we respond to global pandemics, pioneer innovative precision medicine, and improve the safety of our food, medicines and environment.
1001 to 5000 staff
Premier Research
Premier Research International LLC (Premier) is a global leader in clinical research and consulting services with expertise in driving an efficient and effective path to market for the life sciences industry. Premier is built with the needs of biotech in mind, turning breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value. Leveraging deep therapeutic expertise, innovative technology, and product development operational proficiency—from preclinical planning to clinical trial execution and commercialization—our integrated approach offers personalized, end-to-end solutions to identify the pertinent data and insight necessary to make informed decisions earlier and deliver accelerated development timelines for a smarter, faster path to approval. Through our commitment to partner boldly, deliver impact, and foster community, we’re driving change that advances research and improves lives while creating meaningful opportunity for patients, customers, and all Premier team members. Follow our page to learn more about our work—and explore career opportunities to be part of the transformation.
1001 to 5000 staff
Scienion
SCIENION is the leading manufacturer of robust, high performance dispensing automation for applications requiring precise deposition of biological content in ultra-low volumes. Our non-contact technology is ideally suited for loading of oligonucleotides, proteins, antibodies, and glycans onto diagnostics devices. Enabled by very flexible software, our systems are used from early R&D activities, all the way through to manufacturing millions of devices per year. Easy scale up is facilitated by the fact that the same core technologies are engineered into all of our systems. In our portoflio, SCIENION also offers a line of readers, optimized for quantitative array reading on both slides and microtiter plates. Available in colorimetric and fluorescence, these readers are designed with the goal to surpass all pre-existing commercial readers and become the industry standard for assay kits in central labs. Additionally, through our subsidiary Cellenion, we have developed new technology enabling the dispensing of single-cells. The ability to manipulate single-cells has long been a challenge for the scientific community due to their micrometric size and delicate nature. We have developed and patented a breakthrough technology called cellenONE, allowing high throughput isolation and dispensing of single cells onto a wide range of substrates. We also offer our assay development and contract manufacturing services, offering a spectrum of full solutions involving the full manufacturing process including wafer prep, surface functionalization, dicing, content spotting, QC, cartridge assembly, functional QC, and packaging.
51 to 200 staff
